Cynata Therapeutics (ASX:CYP) has received the green light from IP Australia for its Cymerus technology.
The patent application is among the IP licensed exclusively from the Wisconsin Alumni Research Foundation to Cynata.
Cynata has previously been granted a patent in the US by the US Patent and Trademark Office covering the same technology.
CEO DR Ross Macdonald says Cynata’s robust intellectual property around the Cymerus therapeutic stem cell platform technology continues to expand and strengthen.
Shares in Cynata (ASX:CYP) last traded at $1.30